Published in Metabolism on September 01, 2008
Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest (2010) 2.43
Endocrine manifestations of hepatitis C virus infection. Nat Clin Pract Endocrinol Metab (2009) 1.30
Cytokines and HCV-related disorders. Clin Dev Immunol (2012) 1.02
Discrimination of agonist and antagonist forms of CXCL10 in biological samples. Clin Exp Immunol (2012) 0.85
Autoimmune and neoplastic thyroid diseases associated with hepatitis C chronic infection. Int J Endocrinol (2014) 0.84
Chemokine (C-C motif) ligand 2 (CCL2) in sera of patients with type 1 diabetes and diabetic complications. PLoS One (2011) 0.80
Parallel increase of circulating CXCL11 and CXCL10 in mixed cryoglobulinemia, while the proinflammatory cytokine IL-6 is associated with high serum Th2 chemokine CCL2. Clin Rheumatol (2013) 0.78
Peroxisome Proliferator-Activated Receptor- γ in Thyroid Autoimmunity. PPAR Res (2015) 0.76
Mincle Signaling Promotes Con A Hepatitis. J Immunol (2016) 0.75
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05
The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2005) 11.91
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest (2014) 3.10
alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One (2010) 2.94
Common variants of the novel type 2 diabetes genes CDKAL1 and HHEX/IDE are associated with decreased pancreatic beta-cell function. Diabetes (2007) 2.73
Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med (2002) 2.56
Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care (2005) 2.53
Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology (2007) 2.50
Detailed physiologic characterization reveals diverse mechanisms for novel genetic Loci regulating glucose and insulin metabolism in humans. Diabetes (2010) 2.44
Visceral fat in hypertension: influence on insulin resistance and beta-cell function. Hypertension (2004) 2.33
Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol (2008) 2.32
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. Diabetes (2011) 2.21
Thyroid disorders in chronic hepatitis C. Am J Med (2004) 2.19
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia (2015) 2.13
Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. Diabetes (2002) 2.06
Physical activity and insulin sensitivity: the RISC study. Diabetes (2008) 2.03
Myocardial triglyceride content and epicardial fat mass in human obesity: relationship to left ventricular function and serum free fatty acid levels. J Clin Endocrinol Metab (2006) 1.98
Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes (2007) 1.96
Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol (2007) 1.92
Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. Int J Cardiol (2011) 1.89
Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes Care (2005) 1.83
Metabolic effects of visceral fat accumulation in type 2 diabetes. J Clin Endocrinol Metab (2002) 1.73
Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology (2009) 1.71
Meal and oral glucose tests for assessment of beta -cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab (2002) 1.71
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. J Clin Endocrinol Metab (2010) 1.68
Quantification of liver glucose metabolism by positron emission tomography: validation study in pigs. Gastroenterology (2006) 1.66
Obesity and type 2 diabetes: what can be unified and what needs to be individualized? J Clin Endocrinol Metab (2011) 1.63
Variation in the ADIPOQ gene promoter is associated with carotid intima media thickness independent of plasma adiponectin levels in healthy subjects. Eur Heart J (2007) 1.63
Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab (2003) 1.61
Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes. Hum Mol Genet (2009) 1.61
Role of genetics in azoospermia. Urology (2010) 1.59
Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Diabetes Care (2007) 1.57
Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care (2013) 1.56
Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2008) 1.53
Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. Diabetes (2002) 1.51
Breast cancer in systemic sclerosis: results of a cross-linkage of an Italian Rheumatologic Center and a population-based Cancer Registry and review of the literature. Autoimmun Rev (2013) 1.46
IN PATIENTS WITH SUBCLINICAL HYPOTHYROIDISM WHILE IN THERAPY WITH TABLET L-T4, THE LIQUID L-T4 FORMULATION IS MORE EFFECTIVE IN RESTORING EUTHYROIDISM. Endocr Pract (2016) 1.44
Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab (2006) 1.44
Pattern of expression of inflammatory markers in adipose tissue of untreated hypertensive patients. J Hypertens (2010) 1.43
Left ventricular diastolic function and carotid artery wall in elderly athletes and sedentary controls. Biomed Pharmacother (2004) 1.42
Human insulin resistance is associated with increased plasma levels of 12α-hydroxylated bile acids. Diabetes (2013) 1.41
Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. Clin Exp Rheumatol (2012) 1.41
Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab (2006) 1.41
Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol (2007) 1.34
Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care (2007) 1.32
Obesity and type 2 diabetes: what can be unified and what needs to be individualized? Diabetes Care (2011) 1.31
Endocrine manifestations of hepatitis C virus infection. Nat Clin Pract Endocrinol Metab (2009) 1.30
Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother (2004) 1.30
Low-grade systemic inflammation causes endothelial dysfunction in patients with Hashimoto's thyroiditis. J Clin Endocrinol Metab (2006) 1.29
Early hypertension is associated with reduced regional cardiac function, insulin resistance, epicardial, and visceral fat. Hypertension (2008) 1.27
Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev (2011) 1.26
Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. Diabetes (2006) 1.25
Mendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes. Diabetes (2013) 1.25
Hepatitis C virus-related lymphoproliferative disorders: an overview. World J Gastroenterol (2007) 1.22
Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database. Arthritis Rheum (2006) 1.21
Thyroid disorders in chronic hepatitis C virus infection. Thyroid (2006) 1.21
Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol (2014) 1.20
Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. Int J Cancer (2011) 1.19
Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysis. J Clin Endocrinol Metab (2004) 1.16
Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis (2006) 1.16
Prevalence of hypothyroidism and Graves disease in sarcoidosis. Chest (2006) 1.15
Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled study. J Clin Endocrinol Metab (2002) 1.15
Recurrence of cardiovascular events in patients with type 2 diabetes: epidemiology and risk factors. Diabetes Care (2008) 1.14
Lights and shadows concerning platelet products for musculoskeletal regeneration. Front Biosci (Elite Ed) (2011) 1.13
Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes. Diabetes (2011) 1.13
Fatty acid metabolism in the liver, measured by positron emission tomography, is increased in obese individuals. Gastroenterology (2010) 1.13
Incidence and risk factors for stroke in type 2 diabetic patients: the DAI study. Stroke (2007) 1.12
Increased fat mass compensates for insulin resistance in abdominal obesity and type 2 diabetes: a positron-emitting tomography study. Diabetes (2005) 1.11
High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab (2004) 1.11
Effect of acute hyperglycemia on insulin secretion in humans. Diabetes (2002) 1.10
A comparative study of the in vitro antioxidant activity of statins. Int J Cardiol (2003) 1.09
Long-term effects of bariatric surgery on meal disposal and β-cell function in diabetic and nondiabetic patients. Diabetes (2013) 1.09
Differential effect of weight loss on insulin resistance in surgically treated obese patients. Am J Med (2005) 1.08
Dedifferentiated thyroid cancer: a therapeutic challenge. Biomed Pharmacother (2008) 1.08